Syensqo (SYENS) AGM 2025 summary
Event summary combining transcript, slides, and related documents.
AGM 2025 summary
21 Nov, 2025Opening remarks and agenda
Welcomed shareholders and celebrated the first 500 days since the company's formation, emphasizing the mission to lead, inspire, and thrive amid global uncertainty.
CEO Dr. Ilham Kadri opened the meeting, highlighting the company's mission to advance humanity and thrive in a volatile world.
Financial performance review
2024 net sales reached €6.6bn, with underlying EBITDA at €1.42bn and a 21.5% EBITDA margin, delivering on prior commitments.
Free cash flow totaled €390mn, and leverage stood at 1.3x net debt/EBITDA.
Achieved double-digit growth in composite materials despite challenging demand.
Completed a $1.2 billion bond offering.
Dividend announcements
Proposed a gross dividend of €1.62 per share for 2024, stable year-on-year, with a payout ratio increase to 31% from 23%.
Total shareholder rewards increased by 38% over the previous year, with €170mn in dividends and €75mn in share buybacks announced.
Latest events from Syensqo
- 2025 saw lower sales and profit but higher free cash flow; 2026 set for modest growth.SYENS
Q4 202526 Feb 2026 - Record financials, innovation, and bold sustainability targets defined the meeting.SYENS
AGM 20243 Feb 2026 - Q2 saw sequential growth but year-over-year declines, with CapEx delayed and cash flow hit by settlement.SYENS
Q2 20242 Feb 2026 - Q2 2025 sales and EBITDA fell YoY, but margin gains and stable 2025 outlook were maintained.SYENS
Q2 202521 Jan 2026 - Margins and cash flow held firm despite lower sales, with specialty focus and divestment ongoing.SYENS
Q3 202521 Jan 2026 - 2024 delivered strong cash flow and returns; 2025 targets stable EBITDA and strategic focus.SYENS
Q4 202421 Jan 2026 - Q3 2024 delivered organic growth, margin resilience, and a €300 million buyback launch.SYENS
Q3 202421 Jan 2026 - SSc and HS studies lead a robust pipeline, with major catalysts and data readouts expected in 2025–2026.SYENS
Piper Sandler 36th Annual Healthcare Conference12 Jan 2026 - Q1 2025 EBITDA down 15% year-over-year; 2025 outlook and cost-saving targets reaffirmed.SYENS
Q1 202519 Nov 2025